Drugs / VIPIVOTIDE TETRAXETAN
VIPIVOTIDE TETRAXETAN
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07476001 | Mar 2026 → Sep 2027 expected | prostate carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-09-17 | Novartis Pharmaceuticals | Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021 novartis.com ↗ |
| 2021-06-24 | Novartis Pharmaceuticals | Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine novartis.com ↗ |
| 2021-06-03 | Novartis Pharmaceuticals | Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study novartis.com ↗ |
| 2021-03-23 | Novartis Pharmaceuticals | Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer novartis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIPIVOTIDE TETRAXETAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594280 ↗ |
| Known as | DKFZ-PSMA-617 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594280 ↗ |
| Known as | PSMA-617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07476001 ↗ |
| Known as | Vipivotida tetraxetan | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594280 ↗ |
| Modality | Other / unclassified | “targeted radioligand therapy (TRT)” NCT07476001 ↗ |
| Route | Intravenous | “IV at 7.4GBq (200mCi)” NCT07476001 ↗ |